These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 31042587)

  • 21. Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks.
    Su SP; Flashner-Abramson E; Klein S; Gal M; Lee RS; Wu J; Levitzki A; Daly RJ
    Mol Cancer Ther; 2018 May; 17(5):931-942. PubMed ID: 29440449
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NT157 inhibits cell proliferation and sensitizes glioma cells to TRAIL-induced apoptosis by up-regulating DR5 expression.
    Hou YJ; Li D; Wang W; Mao L; Fu X; Sun B; Fan C
    Biomed Pharmacother; 2022 Sep; 153():113502. PubMed ID: 36076591
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multipoint targeting of the PI3K/mTOR pathway in mesothelioma.
    Zhou S; Liu L; Li H; Eilers G; Kuang Y; Shi S; Yan Z; Li X; Corson JM; Meng F; Zhou H; Sheng Q; Fletcher JA; Ou WB
    Br J Cancer; 2014 May; 110(10):2479-88. PubMed ID: 24762959
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Upregulation of IRS1 Enhances IGF1 Response in Y537S and D538G ESR1 Mutant Breast Cancer Cells.
    Li Z; Levine KM; Bahreini A; Wang P; Chu D; Park BH; Oesterreich S; Lee AV
    Endocrinology; 2018 Jan; 159(1):285-296. PubMed ID: 29029116
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor.
    Hu YP; Patil SB; Panasiewicz M; Li W; Hauser J; Humphrey LE; Brattain MG
    Cancer Res; 2008 Oct; 68(19):8004-13. PubMed ID: 18829558
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL).
    Gazi M; Moharram SA; Marhäll A; Kazi JU
    Cancer Lett; 2017 Apr; 392():9-16. PubMed ID: 28159681
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Healthy CD4+ T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia.
    Alameen AA; Simioni C; Martelli AM; Zauli G; Ultimo S; McCubrey JA; Gonelli A; Marisi G; Ulivi P; Capitani S; Neri LM
    Oncotarget; 2016 Aug; 7(34):55690-55703. PubMed ID: 27494886
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Knockdown of insulin receptor substrate 1 reduces proliferation and downregulates Akt/mTOR and MAPK pathways in K562 cells.
    Machado-Neto JA; Favaro P; Lazarini M; Costa FF; Olalla Saad ST; Traina F
    Biochim Biophys Acta; 2011 Aug; 1813(8):1404-11. PubMed ID: 21569802
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
    Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NT157 Inhibits HCC Migration via Downregulating the STAT3/Jab1 Signaling Pathway.
    Yu S; Wang Y; Lv K; Hou J; Li W; Wang X; Guo H; Wang W
    Technol Cancer Res Treat; 2021; 20():15330338211027916. PubMed ID: 34238066
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MicroRNA-100/99a, deregulated in acute lymphoblastic leukaemia, suppress proliferation and promote apoptosis by regulating the FKBP51 and IGF1R/mTOR signalling pathways.
    Li XJ; Luo XQ; Han BW; Duan FT; Wei PP; Chen YQ
    Br J Cancer; 2013 Oct; 109(8):2189-98. PubMed ID: 24030073
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer.
    De Martino MC; van Koetsveld PM; Feelders RA; de Herder WW; Dogan F; Janssen JAMJL; Hofste Op Bruinink D; Pivonello C; Waaijers AM; Colao A; de Krijger RR; Pivonello R; Hofland LJ
    Endocrine; 2019 Jun; 64(3):673-684. PubMed ID: 30838516
    [TBL] [Abstract][Full Text] [Related]  

  • 33. OSI-906 restores the sensitivity of ovarian clear cell carcinoma to cisplatin by targeting the IGF1R/AKT pathway.
    Liu L; Liang C; Zhuo C; Jiang H; Ye H; Ruan T; Song J; Jiang S; Zhang Y; Li X
    Med Oncol; 2022 Jan; 39(2):26. PubMed ID: 34982265
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels.
    Bressanin D; Evangelisti C; Ricci F; Tabellini G; Chiarini F; Tazzari PL; Melchionda F; Buontempo F; Pagliaro P; Pession A; McCubrey JA; Martelli AM
    Oncotarget; 2012 Aug; 3(8):811-23. PubMed ID: 22885370
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors.
    Buck E; Eyzaguirre A; Rosenfeld-Franklin M; Thomson S; Mulvihill M; Barr S; Brown E; O'Connor M; Yao Y; Pachter J; Miglarese M; Epstein D; Iwata KK; Haley JD; Gibson NW; Ji QS
    Cancer Res; 2008 Oct; 68(20):8322-32. PubMed ID: 18922904
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epithelial-mesenchymal transition predicts sensitivity to the dual IGF-1R/IR inhibitor OSI-906 in hepatocellular carcinoma cell lines.
    Zhao H; Desai V; Wang J; Epstein DM; Miglarese M; Buck E
    Mol Cancer Ther; 2012 Feb; 11(2):503-13. PubMed ID: 22161861
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Co-targeting PI3K, mTOR, and IGF1R with small molecule inhibitors for treating undifferentiated pleomorphic sarcoma.
    May CD; Landers SM; Bolshakov S; Ma X; Ingram DR; Kivlin CM; Watson KL; Sannaa GAA; Bhalla AD; Wang WL; Lazar AJ; Torres KE
    Cancer Biol Ther; 2017 Oct; 18(10):816-826. PubMed ID: 29099264
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma.
    Lamhamedi-Cherradi SE; Menegaz BA; Ramamoorthy V; Vishwamitra D; Wang Y; Maywald RL; Buford AS; Fokt I; Skora S; Wang J; Naing A; Lazar AJ; Rohren EM; Daw NC; Subbiah V; Benjamin RS; Ratan R; Priebe W; Mikos AG; Amin HM; Ludwig JA
    J Natl Cancer Inst; 2016 Dec; 108(12):. PubMed ID: 27576731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. AD80, a multikinase inhibitor, exhibits antineoplastic effects in acute leukemia cellular models targeting the PI3K/STMN1 axis.
    Carlos JAEG; Lima K; Costa-Lotufo LV; Leitão A; Machado-Neto JA
    Invest New Drugs; 2021 Aug; 39(4):1139-1149. PubMed ID: 33475938
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insulin Receptor Substrate 1, the Hub Linking Follicle-stimulating Hormone to Phosphatidylinositol 3-Kinase Activation.
    Law NC; Hunzicker-Dunn ME
    J Biol Chem; 2016 Feb; 291(9):4547-60. PubMed ID: 26702053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.